Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

SCTbio

From Wikipedia, the free encyclopedia
SCTbio
IndustryBiotechnology, Pharmaceutical
Founded2021; 5 years ago (2021)
FounderPPF Biotech Group
Headquarters,
Key peopleLuděk Sojka (CEO)[1]
Revenue231,110,000 Czech koruna (2020) Edit this on Wikidata
−2,299,588,000 Czech koruna (2020) Edit this on Wikidata
−2,360,838,000 Czech koruna (2020) Edit this on Wikidata
Total assets7,736,322,000 Czech koruna (2020) Edit this on Wikidata
Number of employees
80 (2022)
ParentPPF (company)
Websitewww.sctbio.com

SCTbio is a Czech biotechnology company that provides contract development and manufacturing services (CDMO) for Advanced Therapy Medicinal Products (ATMPs), utilizing cGMP standards.[2][3]

Operating in Europe and North America, the company specializes in developing autologous cell-based products, cell banking, and all needle-to-needle good manufacturing practice (GMP) operations. These vary from a validated network of apheresis collection sites to product manufacturing, quality control, GMP storage, Qualified Person (QP), and Quality Assurance (QA) release. SCTbio offers worldwide distribution of drug products for both clinical and commercial sales.[4]

History

[edit]

SCTbio was founded on the 1st of July 2021 and is part of the larger PPF Biotech network. SCTbio was initially part of the Sotio group, and SCTbio's CEO, Luděk Sojka, has been part of the PPF Biotech network and Sotio since 2011.[5][6]

On November 1, 2021, Sotio changed its name to SCTbio.[7][2]

Operations

[edit]

SCTbio conducts global operations in Europe and the USA. The cGMP cell manufacturing facility is based in Prague, Czech Republic. The GMP facility features over 2,000 square meters of total space, including a total clean room area of 420m² (4,520 sq ft).[8] The company offers the ability to manufacture genetically modified products that require the separation of viral and non-viral components. This physical segregation minimizes any risk of cross-contamination.

References

[edit]
  1. Sterling, John (2021-03-03). "Putting Pressure On Cells to Kill Cancer". GEN. Retrieved 2022-04-24.
  2. 1 2 "SCTbio". PPF Group. Retrieved 2022-04-24.
  3. "SCTbio a.s., Praha IČO 24662623 - Obchodní rejstřík firem". Kurzy.cz (in Czech). Retrieved 2022-04-24.
  4. "Skupina PPF ve světě. Kde působí firmy zesnulého Petra Kellnera". E15.cz (in Czech). Retrieved 2022-04-24.
  5. "C&G Therapy Manufacturing Automation: Making The Most Of Today's Opportunities". cellandgene.com. Retrieved 2022-04-24.
  6. "Češi jsou blízko světovému objevu. V pražských Holešovicích vyvíjejí lék, který má zatočit s rakovinou". Lidovky.cz (in Czech). 2022-03-25. Retrieved 2022-04-24.
  7. "Change of company name: SOTIO a.s. is now SCTbio a.s." sctbio. Retrieved 2022-04-24.
  8. "Cell mates: SCTbio, CCRM Nordic amp up cell therapy production". Bio Process International. February 5, 2025.